256 related articles for article (PubMed ID: 28597850)
1. The role of peroxisome proliferator-activated receptor gamma in prostate cancer.
Elix C; Pal SK; Jones JO
Asian J Androl; 2018; 20(3):238-243. PubMed ID: 28597850
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.
Elix CC; Salgia MM; Otto-Duessel M; Copeland BT; Yoo C; Lee M; Tew BY; Ann D; Pal SK; Jones JO
Prostate; 2020 Feb; 80(2):162-172. PubMed ID: 31769890
[TBL] [Abstract][Full Text] [Related]
3. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Moss PE; Lyles BE; Stewart LV
Exp Cell Res; 2010 Dec; 316(20):3478-88. PubMed ID: 20932825
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Annicotte JS; Iankova I; Miard S; Fritz V; Sarruf D; Abella A; Berthe ML; Noël D; Pillon A; Iborra F; Dubus P; Maudelonde T; Culine S; Fajas L
Mol Cell Biol; 2006 Oct; 26(20):7561-74. PubMed ID: 17015477
[TBL] [Abstract][Full Text] [Related]
5. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents.
Almahmoud S; Elix CC; Jones JO; Hopkins CR; Vennerstrom JL; Zhong HA
Bioorg Med Chem; 2021 Sep; 46():116368. PubMed ID: 34433102
[TBL] [Abstract][Full Text] [Related]
6. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways.
Chintharlapalli S; Papineni S; Safe S
Mol Pharmacol; 2007 Feb; 71(2):558-69. PubMed ID: 17093136
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K epoxide reductase regulation of androgen receptor activity.
Tew BY; Hong TB; Otto-Duessel M; Elix C; Castro E; He M; Wu X; Pal SK; Kalkum M; Jones JO
Oncotarget; 2017 Feb; 8(8):13818-13831. PubMed ID: 28099154
[TBL] [Abstract][Full Text] [Related]
8. Lycopene and the LXRα agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARγ-LXRα-ABCA1 pathway.
Yang CM; Lu YL; Chen HY; Hu ML
J Nutr Biochem; 2012 Sep; 23(9):1155-62. PubMed ID: 22137263
[TBL] [Abstract][Full Text] [Related]
9. Methyl 2-cyano-3,11-dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells.
Papineni S; Chintharlapalli S; Safe S
Mol Pharmacol; 2008 Feb; 73(2):553-65. PubMed ID: 17989348
[TBL] [Abstract][Full Text] [Related]
10. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity.
Yousefnia S; Momenzadeh S; Seyed Forootan F; Ghaedi K; Nasr Esfahani MH
Gene; 2018 Apr; 649():14-22. PubMed ID: 29369787
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
12. The Androgen Receptor Regulates PPARγ Expression and Activity in Human Prostate Cancer Cells.
Olokpa E; Bolden A; Stewart LV
J Cell Physiol; 2016 Dec; 231(12):2664-72. PubMed ID: 26945682
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma.
Nakamura Y; Suzuki T; Sugawara A; Arai Y; Sasano H
Pathol Int; 2009 May; 59(5):288-93. PubMed ID: 19432669
[TBL] [Abstract][Full Text] [Related]
14. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways.
Lyles BE; Akinyeke TO; Moss PE; Stewart LV
Cell Cycle; 2009 Jan; 8(2):268-77. PubMed ID: 19164938
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
Mansure JJ; Nassim R; Kassouf W
Cancer Biol Ther; 2009 Apr; 8(7):6-15. PubMed ID: 19417560
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
18. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
19. The role of PPARγ in prostate cancer development and progression.
Hartley A; Ahmad I
Br J Cancer; 2023 Apr; 128(6):940-945. PubMed ID: 36510001
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
